Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) Rating Reiterated by Needham & Company LLC

Paterniano Del Favero
Luglio 29, 2017

ALDR has been the subject of a number of other reports.

Alder Biopharmaceuticals, Inc. has a consensus outperform rating from 9 Wall Street analysts, and the number of shares now sold short amount to at least 14.96% of shares outstanding. Russell Investments Group Ltd. now owns 42,416 shares of the biopharmaceutical company's stock valued at $486,000 after buying an additional 2,837 shares during the last quarter. Needham & Company LLC started coverage on Alder BioPharmaceuticals in a research report on Monday, May 15th. Baird Financial Group Inc. now owns 18,441 shares of the biopharmaceutical company's stock valued at $384,000 after buying an additional 1,349 shares during the last quarter.

Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) notched a 12-month high of $34.20 while $51.00 target is by far the most aggressive out of analysts who are now evaluating ALDR, $16.8 higher than the next highest 52-week price estimate. Emerald Mutual Fund Advisers Trust boosted its position in shares of Alder BioPharmaceuticals by 125.5% in the second quarter. State Street Corp now owns 1,758,687 shares of the biopharmaceutical company's stock valued at $36,579,000 after buying an additional 268,187 shares during the last quarter. Baird Financial Group Inc. raised its position in Alder BioPharmaceuticals by 7.9% in the first quarter. The company's market cap is $549.47 million. Finally, Jefferies Group LLC reissued a "buy" rating and set a $43.00 price objective on shares of Alder BioPharmaceuticals in a report on Monday, April 17th.

The share price of the company (ALDR) was up +2.35% during the last trading session, with a high of 11.25 and the volume of Alder BioPharmaceuticals, Inc. shares traded was 940401. The share price has moved backward from its 20 days moving average, trading at a distance of -8.89% and stays -29.42% away from its 50 days moving average. Piper Jaffray maintained the stock with "Buy" rating in Tuesday, June 27 report. Aegis reissued a "buy" rating and set a $41.00 price objective on shares of Alder BioPharmaceuticals in a report on Tuesday, April 25th. ALDR's total short interest was 9.18M shares in July as published by FINRA. Finally, American Century Companies Inc. raised its position in Alder BioPharmaceuticals by 5.7% in the first quarter. State Board of Administration of Florida Retirement System boosted its position in shares of Alder BioPharmaceuticals by 0.7% in the fourth quarter. Alder Biopharmaceuticals, Inc. (ALDR) has made its way to a 12-month decline of -65.07%. The stock now has an average rating of "Buy" and an average price target of $35.00. Alder BioPharmaceuticals has a 12 month low of $10.05 and a 12 month high of $36.48. The biopharmaceutical company reported ($1.99) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.95) by $1.04. During the same period in the previous year, the firm posted ($0.76) earnings per share. On average, equities research analysts anticipate that Alder BioPharmaceuticals will post ($6.27) EPS for the current year. They issued a "sell" rating and a $13.00 price objective on the stock. If you are accessing this news story on another site, it was illegally copied and republished in violation of USA & worldwide copyright & trademark legislation.

09/30/2016 - Brean Capital began new coverage on Alder BioPharmaceuticals, Inc. giving the company a " rating. If you are accessing this report on another domain, it was illegally stolen and republished in violation of worldwide copyright legislation. The correct version of this report can be read at https://www.chaffeybreeze.com/2017/07/27/alder-biopharmaceuticals-inc-aldr-upgraded-to-buy-by-zacks-investment-research-updated.html.

In other news, Director Stephen M. Dow bought 25,000 shares of the firm's stock in a transaction that occurred on Tuesday, July 18th. The mean target of $37.50 should be compared with the price when the stock was languishing around $10.05 a share. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.

Altre relazioni OverNewsmagazine

Discuti questo articolo

SEGUI I NOSTRI GIORNALE